6D·

Bayer shares shoot up 9% - these are the reasons!

Bayer has made progress in a clinical trial with Asundexian, a drug for the treatment of strokes. Asundexian has blockbuster potential and catapulted the share price up more than 9% on Monday.

Summarized for you

Bayer makes progress with Asundexian, shares up 9%.

Drug lowers stroke risk, FDA fast-track.

Market potential of Asundexian at 3 billion euros.

Report: The year-end rally rolls on

https://www.wallstreet-online.de/nachricht/20200506-milliardenmarkt-sicht-bayer-aktie-schiesst-9-plus-gruende

www.wallstreet-online.deBayer-Aktie schießt 10% ins Plus – das sind die Gründe!

12 Comentários

Smudo@Smudeo

Cool now only minus 70%

•

Ver todas as 7 restantes respostas

Felix@Shareholder

Thought I wasn't seeing right this morning. According to my experience and my little hand, the number at Bayer should be red. But the fact is. Green😲
How do you see Bayer - hands off because of casa Monsanto or potential for rebound?

••

Tenbagger2024@Tenbagger2024

@Shareholder
I am cautious about making a forecast for bayer

••

Global I.@gloinvest

Great - I'm only 54% behind. First purchase was in 2008 and is in the tax-free portfolio. Together with Mercedes and BASF.

••

Tenbagger2024@Tenbagger2024

@gloinvest
Mercedes I am also still slightly in the red.
But the dividend is a consolation.
Bayer and BASF have never been my cup of tea.
I'm positioned differently in the pharmaceutical sector, where I also like to focus on niches. Because they always have takeover potential.

••